Epizyme To Participate in H.C. Wainwright Global Investment Conference
05/17/2022 - 07:00 AM
CAMBRIDGE, Mass. --(BUSINESS WIRE)--
Epizyme Grant Bogle , President and Chief Executive Officer, and Shefali Agarwal , Senior Medical Advisor and Interim Chief Medical and Development Officer, will present at the H.C. Wainwright Global Investment Conference .
A pre-recorded fireside chat will be available to play on demand stating at 7:00am EST on Tuesday, May 24, 2022 . It can be found in the investor section of the Company’s website at www.epizyme.com and will be archived after 60 days following the presentation.
About Epizyme, Inc.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer through novel epigenetic medicines. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take and based on a deep understanding of the patients that may benefit from them. The Company aspires to change the standard-of-care for patients and physicians by developing medicines with fundamentally new mechanisms of action. For more information, visit www.epizyme.com .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220517005278/en/
Media: Erin Graves
media@epizyme.com
Investors: Caitlin Stern
cstern@realchemistry.com
Source: Epizyme, Inc.
EPZM Rankings
N/A Ranked by Stock Gains
EPZM Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About EPZM
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
